This is an aggregated industry headline. Read the full story at Drug Channels →
Drug Channels News Roundup, May 2026: My $0.02 on Optum Rx's Transparency, Must-Read 340B History, PBM Unbundling Update, PA Delays, and Vegas Fun
By Adam J. Fein, Ph.D.Summer unofficially kicked off last weekend. So fire up the grill and enjoy these noteworthy delicacies, seared to perfection on the Drug Channels barbeque: Why Optum Rx Is Accelerating Its Transparency Strategy The Most Important 340B Paper You'll Ever Read Blue Shield of Cali
By Drug Channels
· May 27, 2026
· via Drug Channels
RxInsider combines reported facts with industry analysis and informed inference. Forward-looking reads, market commentary, and interpretive framing reflect analysis of available reporting and known facts, not confirmed outcomes.
Tags
theweekformat:headlineheadlineDrug Channels
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from The Week
All The Week →
The WeekFiercePharma ↗
Amid efforts in Germany to retool the country's drug spending, the U.S. is launching an investigation into wha…
The WeekFierceBiotech ↗
Exelixis' next franchise drug, zanzalintinib, has hit a clinical setback, although at least two groups of anal…
The WeekBriefing
China grants CARsgen approval for a Claudin18.2-targeted therapy, marking the first CAR-T authorized for solid…